NCT00064727View on ClinicalTrials.gov

Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 9, 2003

Study Completion Date

April 11, 2007

Conditions
Congestive Heart Failure
Interventions
DRUG

Avandia (Rosiglitazone)

DRUG

Avanclia (Rosiqlitazone)

Trial Locations (2)

20814

Suburban Hospital, Bethesda

20892

National Heart, Lung and Blood Institute (NHLBI), 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00064727 - Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes | Biotech Hunter | Biotech Hunter